Research progress on risk factors of recurrent atrial fibrillation after radiofrequency catheter ablation_Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Authors：

ZHANG Qi , YAO Xingxing , LIU Honghao , SONG Tao , JIAO Zhouyang ,  LIU Chao

Department of Cardiac Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, P.R.China;

Corresponding author：

LIU Chao, Email: Liubeilun@sohu.com

Keywords：

Atrial fibrillation; radiofrequency catheter ablation; recurrence

DOI：

10.7507/1007-4848.201511017

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Atrial fibrillation (AF) is one of the most common clinical arrhythmia. In recent years, basic researches on AF have made a great progress. Radiofrequency catheter ablation (RFCA) has been widely used as a nonpharmacological treatment for AF. However, recurrence rate of AF is high even after RFCA. So we need to find the influencing factors of the recurrence of AF early. Choosing patients who have better indications can improve the success rate of RFCA and reduce recurrence rate.

Citation： ZHANG Qi, YAO Xingxing, LIU Honghao, SONG Tao, JIAO Zhouyang, LIU Chao. Research progress on risk factors of recurrent atrial fibrillation after radiofrequency catheter ablation. Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2017, 24(8): 649-651. doi: 10.7507/1007-4848.201511017 Copy

1.	周自强, 胡大一, 陈捷, 等. 中国心房颤动现状的流行病学研究.中华内科杂志, 2004, 43(7): 491-494.
2.	Li Y, Wu YF, Chen KP, et al. Prevalence of atrial fibrillation in China and its risk factors. Biomed Environ Sci, 2013, 26(9): 709-716.
3.	方东平, 郭成军, 李果, 等. 慢性心房颤动射频消融术后应用氯沙坦联合胺碘酮治疗对心房颤动复发及心房结构的影响. 新乡医学院学报, 2013, 30(9): 730-732.
4.	张鹤萍, 胡大一. 非心瓣膜疾病性心房颤动与血栓栓塞. 中华心血管病杂志, 2005, 33(10): 966-968.
5.	European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery, Camm AJ, et al. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European society of cardiology(ESC). Eur Heart J, 2010, 31(19): 2369-2429.
6.	武忠, 陈保俊, 曹彬, 等. 心内直视下射频消融改良迷宫术治疗心房颤动. 中国胸心血管外科临床杂志, 2007, 14(4): 308-309.
7.	邬晓臣, 张进宝. 二尖瓣置换同期行双极射频消融术治疗风湿性二尖瓣病变合并心房颤动的疗效分析. 中国胸心血管外科临床杂志, 2014, 21(6): 827-829.
8.	秦牧, 于胜波, 赵庆彦, 等. 抑郁对心房颤动患者环肺静脉射频消融术后复发的影响. 中华心律失常学杂志, 2011, 15(4): 268-271.
9.	Kottkamp H. Catheter ablation of atrial fibrillation: on the pathophysiology of the arrhythmia and the impact of cardiac risk factor management. J Am Coll Cardiol, 2014, 64(21): 2232-2234.
10.	沈启明, 刘伏元. 阵发性心房颤动患者射频消融术后心房颤动晚期复发的相关因素. 中国临床保健杂志, 2013, 16(3): 268-270.
11.	符竣, 王波, 陶凉, 等. 两种不同射频消融方式治疗风湿性心瓣膜病合并永久性心房颤动的疗效比较. 中国胸心血管外科临床杂志, 2013, 20(3): 304-307.
12.	付明浦, 薛松, 黄日太, 等. 心内直视手术同期行单极或双极射频消融治疗心房颤动的效果比较. 中国胸心血管外科临床杂志, 2015, 22(9): 851-854.
13.	Sestito A, Molina E. Atrial fibrillation and the pharmacological treatment: the role of propafenone. Eur Rev Med Pharmacol Sci, 2012,16(2): 242-253.
14.	杨嵩, 张希, 唐白云, 等. 永久性心房颤动外科双极射频消融术的效果. 中国胸心血管外科临床杂志, 2012, 19(3): 254-257.
15.	张新勇, 马长生. 接受射频消融治疗的女性房颤患者危险因素分析. 中国医学前沿杂志(电子版), 2010, 2(3): 59-62.
16.	王莹惠, 王波, 付琳. 房颤射频消融术后 AF 早期复发的预测因素. 心脏杂志, 2014, 26(6): 734-736.
17.	林德仿. 阵发性心房颤动患者射频消融术后心房颤动晚期复发的相关因素分析. 现代医院, 2014, 14(12): 47-50.
18.	Annoura M, Ogawa M, Kumagai K, et al. Cholesterol paradox in patients with paroxysmal atrial fibrillation. Cardiology, 1999, 92(1): 21-27.
19.	Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation, 2000, 102(18): 2165-2168.
20.	梁海雁, 骈晶, 姚传臣. 瑞舒伐他汀对阵发性房颤患者 C 反应蛋白、左心房内径及房颤复发率的影响. 河北医药, 2012, 34(19): 2907-2908.
21.	Letsas KP, Weber R, Burkle G, et al. Pre-ablative predictors of atrial fibrillation recurrence following pulmonary vein isolation: the potential role of inflammation. Europace, 2009, 11(2): 158-163.
22.	Pandozi C, Santini M. Update on atrial remodelling owing to rate; does atrial fibrillation always 'beget' atrial fibrillation? Eur Heart J, 2001, 22(7): 541-553.
23.	李菲, 孟旭. 术前左心房内径对外科射频术治疗心房颤动疗效的影响. 中国胸心血管外科临床杂志, 2013, 20(1): 38-42.
24.	唐宏萍, 辛辉, 魏延津. 瑞舒伐他汀的剂量大小对房颤射频消融术后复发的影响. 山东医学高等专科学校学报, 2015, 37(1): 63-67.
25.	Ganotakis ES, Mikhailidis DP, Vardas PE. Atrial fibrillation, inflammation and statins. Hellenic J Cardiol, 2006, 47(2): 51-53.
26.	谢咏梅, 宝花, 金花. 他汀类药物在治疗房颤中的作用分析. 内蒙古医学杂志, 2013, 45(1): 99-100.
27.	Stevenson IH, Teichtahl H, Cunnington D, et al. Prevalence of sleep disordered breathing in paroxysmal and persistent atrial fibrillation patients with normal left ventricular function. Eur Heart, 2008, 29(13): 1662-1669.
28.	Ng CY, Liu T, Shehata M, et al. Meta-analysis of obstructive sleep apnea as predictor of atrial fibrillation recurrence after catheter ablation. Am J Cardiol, 2011, 108(1): 47-51.
29.	Naruse Y, Tada H, Satoh M, et al. Concomitant obstructive sleep apnea increases the recurrence of atrial fibrillation following radiofrequency catheter ablation of atrial fibrillation: Clinical impact of continuous positive airway pressure therapy. Heart Rhythm, 2013, 10(3): 331-337.
30.	Soliman EZ, Prineas RJ, Go AS, et al. Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC). Am Heart, 2010, 159(6): 1102-1107.
31.	Naruse Y, Tada H, Sekiguchi Y, et al. Concomitant chronic kidney disease increases the recurrence of atrial fibrillation after catheter ablation of atrial fibrillation: A mid-term follow-up. Heart Rhythm, 2011, 8(3): 335-341.
32.	Leong-Sit P, Roux JF, Zado E, et al. Antiarrhythmics after ablation of atrial fibrillation (5A Study): six-month follow-up study. Circ Arrhythm Electrophysiol, 2011, 4: 11-14.
33.	den Uijl DW, Delgado V, Bertini M, et al. Impact of left atrial fibrosis and left atrial size on the outcome of catheter ablation for atrial fibrillation. Heart, 2011, 97(22): 1847-1851.
34.	Catena C, Colussi G, Marzano L, et al. Aldosterone and the heart: from basic research to clinical evidence. Horm Metab Res, 2012, 44(3): 181-187.
35.	雷涛, 刘小慧, 罗太阳, 等. 培哚普利联合醛固酮受体拮抗剂对心房纤颤犬心房电重构的影响. 心肺血管病杂志, 2010, 29(3): 233-237.
36.	Pellman J, Lyon RC, Sheikh F. Extracellular matrix remodeling in atrial fibrosis: Mechanisms and fibrillation. J Mol Cell Cardiol, 2010, 48(3): 461-467.
37.	卢艳雨, 余江坤, 鲁艳娇, 等. 螺内酯对持续性房颤患者射频消融术后的临床疗效分析. 河南医学研究, 2015, 24(4): 12-14.
38.	周勇, 李莉, 徐志厶, 等. 心内膜微波消融治疗永久性心房颤动. 中华心血管病杂志, 2008, 36(5): 402-403.
39.	伍继初, 罗参香, 欧阳泽伟. 胺碘酮及氯沙坦对慢性房颤射频消融术后心房结构及房颤复发的影响. 中国临床药理学与治疗学, 2015, 2(3): 318-322.
40.	梁珍玲, 孙叶海, 彭卫平. 厄贝沙坦联合胺碘酮治疗阵发性心房颤动的疗效. 中国老年学杂志, 2012, 32(13): 2836-2837.
41.	Beukema WP, Sie HT, Misier AR, et al. Predictive factors of sustained sinus rhythm and recurrent atrial fibrillation after a radiofrequency modified Maze procedure. Eur J Cardiothorac Surg, 2008, 34(4): 771-775.
42.	Fasol R, Mdinhart J, Binder T. A modified and simplified radiofrequency ablation in patients with mitral valve disease. J Thorac Cardiovasc Surg, 2005, 129(1): 215-217.
43.	Parvez B, Shoemaker MB, Muhammad R, et al. Common genetic polymorphism at 4q25 locus predicts atrial fibrillation recurrence after successful cardioversion. Heart Rhythm, 2013, 10(6): 849-855..
44.	Benjamin Shoemaker M, Muhammad R, Parvez B, et al. Common atrial fibrillation risk alleles at 4q25 predict recurrence after catheter-based atrial fibrillation ablation. Heart Rhythm, 2013, 10(3): 394-400.

1. 周自强, 胡大一, 陈捷, 等. 中国心房颤动现状的流行病学研究.中华内科杂志, 2004, 43(7): 491-494.
2. Li Y, Wu YF, Chen KP, et al. Prevalence of atrial fibrillation in China and its risk factors. Biomed Environ Sci, 2013, 26(9): 709-716.
3. 方东平, 郭成军, 李果, 等. 慢性心房颤动射频消融术后应用氯沙坦联合胺碘酮治疗对心房颤动复发及心房结构的影响. 新乡医学院学报, 2013, 30(9): 730-732.
4. 张鹤萍, 胡大一. 非心瓣膜疾病性心房颤动与血栓栓塞. 中华心血管病杂志, 2005, 33(10): 966-968.
5. European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery, Camm AJ, et al. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European society of cardiology(ESC). Eur Heart J, 2010, 31(19): 2369-2429.
6. 武忠, 陈保俊, 曹彬, 等. 心内直视下射频消融改良迷宫术治疗心房颤动. 中国胸心血管外科临床杂志, 2007, 14(4): 308-309.
7. 邬晓臣, 张进宝. 二尖瓣置换同期行双极射频消融术治疗风湿性二尖瓣病变合并心房颤动的疗效分析. 中国胸心血管外科临床杂志, 2014, 21(6): 827-829.
8. 秦牧, 于胜波, 赵庆彦, 等. 抑郁对心房颤动患者环肺静脉射频消融术后复发的影响. 中华心律失常学杂志, 2011, 15(4): 268-271.
9. Kottkamp H. Catheter ablation of atrial fibrillation: on the pathophysiology of the arrhythmia and the impact of cardiac risk factor management. J Am Coll Cardiol, 2014, 64(21): 2232-2234.
10. 沈启明, 刘伏元. 阵发性心房颤动患者射频消融术后心房颤动晚期复发的相关因素. 中国临床保健杂志, 2013, 16(3): 268-270.
11. 符竣, 王波, 陶凉, 等. 两种不同射频消融方式治疗风湿性心瓣膜病合并永久性心房颤动的疗效比较. 中国胸心血管外科临床杂志, 2013, 20(3): 304-307.
12. 付明浦, 薛松, 黄日太, 等. 心内直视手术同期行单极或双极射频消融治疗心房颤动的效果比较. 中国胸心血管外科临床杂志, 2015, 22(9): 851-854.
13. Sestito A, Molina E. Atrial fibrillation and the pharmacological treatment: the role of propafenone. Eur Rev Med Pharmacol Sci, 2012,16(2): 242-253.
14. 杨嵩, 张希, 唐白云, 等. 永久性心房颤动外科双极射频消融术的效果. 中国胸心血管外科临床杂志, 2012, 19(3): 254-257.
15. 张新勇, 马长生. 接受射频消融治疗的女性房颤患者危险因素分析. 中国医学前沿杂志(电子版), 2010, 2(3): 59-62.
16. 王莹惠, 王波, 付琳. 房颤射频消融术后 AF 早期复发的预测因素. 心脏杂志, 2014, 26(6): 734-736.
17. 林德仿. 阵发性心房颤动患者射频消融术后心房颤动晚期复发的相关因素分析. 现代医院, 2014, 14(12): 47-50.
18. Annoura M, Ogawa M, Kumagai K, et al. Cholesterol paradox in patients with paroxysmal atrial fibrillation. Cardiology, 1999, 92(1): 21-27.
19. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation, 2000, 102(18): 2165-2168.
20. 梁海雁, 骈晶, 姚传臣. 瑞舒伐他汀对阵发性房颤患者 C 反应蛋白、左心房内径及房颤复发率的影响. 河北医药, 2012, 34(19): 2907-2908.
21. Letsas KP, Weber R, Burkle G, et al. Pre-ablative predictors of atrial fibrillation recurrence following pulmonary vein isolation: the potential role of inflammation. Europace, 2009, 11(2): 158-163.
22. Pandozi C, Santini M. Update on atrial remodelling owing to rate; does atrial fibrillation always 'beget' atrial fibrillation? Eur Heart J, 2001, 22(7): 541-553.
23. 李菲, 孟旭. 术前左心房内径对外科射频术治疗心房颤动疗效的影响. 中国胸心血管外科临床杂志, 2013, 20(1): 38-42.
24. 唐宏萍, 辛辉, 魏延津. 瑞舒伐他汀的剂量大小对房颤射频消融术后复发的影响. 山东医学高等专科学校学报, 2015, 37(1): 63-67.
25. Ganotakis ES, Mikhailidis DP, Vardas PE. Atrial fibrillation, inflammation and statins. Hellenic J Cardiol, 2006, 47(2): 51-53.
26. 谢咏梅, 宝花, 金花. 他汀类药物在治疗房颤中的作用分析. 内蒙古医学杂志, 2013, 45(1): 99-100.
27. Stevenson IH, Teichtahl H, Cunnington D, et al. Prevalence of sleep disordered breathing in paroxysmal and persistent atrial fibrillation patients with normal left ventricular function. Eur Heart, 2008, 29(13): 1662-1669.
28. Ng CY, Liu T, Shehata M, et al. Meta-analysis of obstructive sleep apnea as predictor of atrial fibrillation recurrence after catheter ablation. Am J Cardiol, 2011, 108(1): 47-51.
29. Naruse Y, Tada H, Satoh M, et al. Concomitant obstructive sleep apnea increases the recurrence of atrial fibrillation following radiofrequency catheter ablation of atrial fibrillation: Clinical impact of continuous positive airway pressure therapy. Heart Rhythm, 2013, 10(3): 331-337.
30. Soliman EZ, Prineas RJ, Go AS, et al. Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC). Am Heart, 2010, 159(6): 1102-1107.
31. Naruse Y, Tada H, Sekiguchi Y, et al. Concomitant chronic kidney disease increases the recurrence of atrial fibrillation after catheter ablation of atrial fibrillation: A mid-term follow-up. Heart Rhythm, 2011, 8(3): 335-341.
32. Leong-Sit P, Roux JF, Zado E, et al. Antiarrhythmics after ablation of atrial fibrillation (5A Study): six-month follow-up study. Circ Arrhythm Electrophysiol, 2011, 4: 11-14.
33. den Uijl DW, Delgado V, Bertini M, et al. Impact of left atrial fibrosis and left atrial size on the outcome of catheter ablation for atrial fibrillation. Heart, 2011, 97(22): 1847-1851.
34. Catena C, Colussi G, Marzano L, et al. Aldosterone and the heart: from basic research to clinical evidence. Horm Metab Res, 2012, 44(3): 181-187.
35. 雷涛, 刘小慧, 罗太阳, 等. 培哚普利联合醛固酮受体拮抗剂对心房纤颤犬心房电重构的影响. 心肺血管病杂志, 2010, 29(3): 233-237.
36. Pellman J, Lyon RC, Sheikh F. Extracellular matrix remodeling in atrial fibrosis: Mechanisms and fibrillation. J Mol Cell Cardiol, 2010, 48(3): 461-467.
37. 卢艳雨, 余江坤, 鲁艳娇, 等. 螺内酯对持续性房颤患者射频消融术后的临床疗效分析. 河南医学研究, 2015, 24(4): 12-14.
38. 周勇, 李莉, 徐志厶, 等. 心内膜微波消融治疗永久性心房颤动. 中华心血管病杂志, 2008, 36(5): 402-403.
39. 伍继初, 罗参香, 欧阳泽伟. 胺碘酮及氯沙坦对慢性房颤射频消融术后心房结构及房颤复发的影响. 中国临床药理学与治疗学, 2015, 2(3): 318-322.
40. 梁珍玲, 孙叶海, 彭卫平. 厄贝沙坦联合胺碘酮治疗阵发性心房颤动的疗效. 中国老年学杂志, 2012, 32(13): 2836-2837.
41. Beukema WP, Sie HT, Misier AR, et al. Predictive factors of sustained sinus rhythm and recurrent atrial fibrillation after a radiofrequency modified Maze procedure. Eur J Cardiothorac Surg, 2008, 34(4): 771-775.
42. Fasol R, Mdinhart J, Binder T. A modified and simplified radiofrequency ablation in patients with mitral valve disease. J Thorac Cardiovasc Surg, 2005, 129(1): 215-217.
43. Parvez B, Shoemaker MB, Muhammad R, et al. Common genetic polymorphism at 4q25 locus predicts atrial fibrillation recurrence after successful cardioversion. Heart Rhythm, 2013, 10(6): 849-855..
44. Benjamin Shoemaker M, Muhammad R, Parvez B, et al. Common atrial fibrillation risk alleles at 4q25 predict recurrence after catheter-based atrial fibrillation ablation. Heart Rhythm, 2013, 10(3): 394-400.

Previous Article
Research progress of splanchnicectomy for cancer pain
Next Article
Removal of anterior mediastinal bronchogenic cysts by uniportal thoracoscopy in 26 patients

Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Research progress on risk factors of recurrent atrial fibrillation after radiofrequency catheter ablation

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content